Bioinformatics analysis (UbiBrowser) and literature mining were used to predict potential FBXO22-regulated targets, including KDM4A, p53, CD147, PTEN, BAG3, LKB1, KLF4, BACH1, Snail, and HDM2
The prescribing provider should carefully evaluate concurrent medications and individualize dose adjustments as appropriate
Products are packaged using controlled processes designed to help maintain compound integrity during storage and transit
There is no validated human dosage, and no studies confirm injection safety in humans
Reported side effects are generally mild and may include localized pain or redness at the injection site
Individual variation in response rates reflects genetic factors, the underlying cause of hair loss, and baseline follicle health